Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

New approach could free cancer patients from steroid side effects

NCT ID NCT04375228

Summary

This study tests whether two existing drugs, rituximab or tocilizumab, can help cancer patients stop taking steroids needed to manage side effects from immunotherapy. Participants have advanced cancer and developed immune-related side effects requiring prolonged steroid use, which can cause significant problems like weight gain, diabetes, and bone loss. The goal is to see if these alternative treatments can effectively control side effects while allowing patients to discontinue steroids.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for ADVANCED SOLID TUMOR are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Contacts and locations

Locations

  • Columbia University Irving Medical Center, Herbert Irving Comprehensive Cancer Center

    New York, New York, 10032, United States

  • Johns Hopkins

    Baltimore, Maryland, 21224, United States

  • Memorial Sloan Kettering Cancer Center

    New York, New York, 10022, United States

Conditions

Explore the condition pages connected to this study.